Dr. Richard DiMarchi is a globally recognized expert in the field of biochemistry, particularly known for his groundbreaking work in peptide and protein-based therapeutics. With over 35 years of experience, Dr. DiMarchi has significantly contributed to the development of synthetic peptides and their application in treating various diseases. His pioneering research has led to advancements in diabetes treatment and obesity management, highlighting the practical experience and real-world application of therapeutic peptides.
Dr. DiMarchi’s notable publications include:
Dr. DiMarchi’s work is marked by his deep expertise and authoritative voice in biotechnology, earning him numerous accolades, including induction into the National Inventors Hall of Fame. These honors underscore his trustworthiness and influential role in advancing peptide science.
Dr. Anna Kazmierczak is an eminent researcher specializing in neuropeptides and their influence on human physiology and behavior. Her expertise lies in understanding the complex interplay between peptides and neurotransmission, elucidating crucial pathways involved in mood regulation and social behavior. With over two decades of research experience, Dr. Kazmierczak has successfully blended her biochemical expertise with neurophysiological insights, proving invaluable in treating disorders linked to cognitive function.
Key publications by Dr. Kazmierczak include:
Dr. Kazmierczak’s contributions are characterized by meticulous research and innovative exploration of peptide interactions in the brain. Her work not only emphasizes the importance of peptides in maintaining mental health but also cements her authoritative position in peptide neurobiology.
Burton, C. S., & Mishra, K. (2022). Pharmacologic therapeutic options for sexual dysfunction. Current Opinion in Obstetrics & Gynecology, 34(6), 402–408. https://doi.org/10.1097/gco.0000000000000821
Cipriani, S., Alfaroli, C., Maseroli, E., & Vignozzi, L. (2022). An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opinion on Pharmacotherapy, 24(1), 15–21. https://doi.org/10.1080/14656566.2022.2132144
Clayton, A. H., Kingsberg, S. A., & Goldstein, I. (2018). Evaluation and management of Hypoactive Sexual Desire Disorder. Sexual Medicine, 6(2), 59–74. https://doi.org/10.1016/j.esxm.2018.01.004
Da Silva Lara, L. A., Rufino, A. C., Oliveira, F. F., Rossato, S., Borges, C. S., & Reis, R. M. (2022). Female sexual dysfunctions: an overview on the available therapeutic interventions. Minerva Obstetrics and Gynecology, 74(3). https://doi.org/10.23736/s2724-606x.22.04966-1
Dhillon, S., & Keam, S. J. (2019). Bremelanotide: First approval. Drugs, 79(14), 1599–1606. https://doi.org/10.1007/s40265-019-01187-w
Diamond, L. E., Earle, D. C., Rosen, R. C., Willett, M. S., & Molinoff, P. B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51–59. https://doi.org/10.1038/sj.ijir.3901139
Diamond, L., Earle, D., Garcia, W., & Spana, C. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 65(4), 755–759. https://doi.org/10.1016/j.urology.2004.10.060
Edinoff, A. N., Sanders, N. M., Lewis, K. B., Apgar, T. L., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). Bremelanotide for treatment of female hypoactive sexual desire. Neurology International, 14(1), 75–88. https://doi.org/10.3390/neurolint14010006
Gelman, F., & Atrio, J. (2017). Flibanserin for hypoactive sexual desire disorder: place in therapy. Therapeutic Advances in Chronic Disease, 8(1), 16–25. https://doi.org/10.1177/2040622316679933
Hallam, N. T. J., Spana, N. C., Earle, N. D. C., Shadiack, N. a. M., & Sharma, N. S. D. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137–1144. https://doi.org/10.2174/156802607780906681
Kumar, R., & Nehra, A. (2011). Central nervous system agents and erectile dysfunction. Urologic Clinics of North America, 38(2), 165–173. https://doi.org/10.1016/j.ucl.2011.03.006
Lee, J. H., Lee, J. E., Harsh, V., & Clayton, A. H. (2022). Pharmacotherapy for sexual dysfunction in women. Current Psychiatry Reports, 24(2), 99–109. https://doi.org/10.1007/s11920-022-01322-7
Molinoff, P. B., Shadiack, A. M., Earle, D., Diamond, L. E., & Quon, C. Y. (2003). PT‐141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994(1), 96–102. https://doi.org/10.1111/j.1749-6632.2003.tb03167.x
Nappi, R. E., Tiranini, L., Martini, E., Bosoni, D., Righi, A., & Cucinella, L. (2022). Medical treatment of female sexual dysfunction. Urologic Clinics of North America, 49(2), 299–307. https://doi.org/10.1016/j.ucl.2022.02.001
Pettigrew, J. A., & Novick, A. M. (2021). Hypoactive Sexual Desire Disorder in Women: Physiology, assessment, diagnosis, and treatment. Journal of Midwifery & Women S Health, 66(6), 740–748. https://doi.org/10.1111/jmwh.13283
Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. International Journal of Impotence Research, 16(2), 135–142. https://doi.org/10.1038/sj.ijir.3901200
Spielmans, G. I., & Ellefson, E. M. (2023). Small effects, questionable outcomes: Bremelanotide for hypoactive sexual desire disorder. The Journal of Sex Research, 61(4), 540–561. https://doi.org/10.1080/00224499.2023.2175192
Sweeney, P., Gimenez, L. E., Hernandez, C. C., & Cone, R. D. (2023). Targeting the central melanocortin system for the treatment of metabolic disorders. Nature Reviews Endocrinology, 19(9), 507–519. https://doi.org/10.1038/s41574-023-00855-y
Yuan, X., & Tao, Y. (2022). Ligands for melanocortin receptors: beyond Melanocyte-Stimulating hormones and adrenocorticotropin. Biomolecules, 12(10), 1407. https://doi.org/10.3390/biom12101407
Zhong, Q., & Anderson, Y. (2022). Management of Hypertension with Female Sexual Dysfunction. Medicina, 58(5), 637. https://doi.org/10.3390/medicina58050637
There are no reviews yet.